Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of benzamide compound in preparation of medicine for activating latent human immunodeficiency virus

A technology of HIV and benzamide, applied in the field of medicine, to achieve long-lasting, accelerated clearance, and high-efficiency effects

Inactive Publication Date: 2014-10-01
ARIS NANTONG PHARMA +1
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no research report on the application of chidamide as a latent drug for activating HIV, that is, the functional cure of AIDS at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of benzamide compound in preparation of medicine for activating latent human immunodeficiency virus
  • Application of benzamide compound in preparation of medicine for activating latent human immunodeficiency virus
  • Application of benzamide compound in preparation of medicine for activating latent human immunodeficiency virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Chidamide activates the detection of latent HIV activity on the J-lat full length clone10.6 (abbreviated as J-lat10.6) cell model

[0042] In this example, the selected HIV latently infected cell model is the J-lat10.6 strain (Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J22:1868-1877, 2003). The J-lat10.6 strain cell is an A6 clone strain established after the HIV pseudovirus carrying the green fluorescent protein gene is infected with human T cells, and it is a commonly used HIV latently infected cell membrane in the world. The biological characteristic of this cell model is the integration of HIV pseudogenes, but the viral genes are not expressed (gene silencing). Since green fluorescent protein can be observed on living cells and detected by flow cytometry, green fluorescent protein is used as the reporter gene of this model, that is, as a marker of whether latently infect...

Embodiment 2

[0046] Example 2: Detection of chidamide activation of latent HIV activity on ACH-2 latently infected cell model (live HIV model)

[0047] In this example, the selected HIV latently infected cell model is the ACH-2 cell line (Folks TM, Clouse KA , Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor a induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA86:2365-2368, 1989.). The cells are derived from CEM cells and were first isolated from a 4-year-old Caucasian girl with acute lymphoblastic leukemia. Each ACH-2 cell is infected with a proviral HIV virus, which can express p24 in a low amount, and can be induced by TNF-α to express a large amount of HIV infectious virions. The system is a live HIV latent model, which can better simulate HIV latent cells in vivo. The sources of medicines used are as described in Implementation 1.

[0048] The relevant technical solutions are as follows: 1. Each we...

Embodiment 3

[0050] Example 3: Detection of chidamide activation of latent HIV activity on J1.1 latently infected cell model (live HIV model)

[0051] In this example, the selected HIV latently infected cell model is the J1.1 cell line (Perez VL, Rowe T , Justement JS, Butera ST, June CH, Folks TM. An HIV-1-infected T cell clone defective in IL-2production and Ca2+ mobilization after CD3stimulation. J Immunol 147:3145-3148, 1991.). From Jurkat cells, it is a cell line with latent HIV infection isolated from HIV-infected Jurkat cells. The system is also a living HIV latent model, which can better simulate HIV latent cells in vivo. The sources of drugs used are as described in Implementation 1.

[0052] The relevant technical solutions are as follows: 1. Each well contains 1*10 4 A 96-well plate was plated with J1.1 cells. 2. Chidamide, and control drugs SAHA, TSA, and Apcidin were incubated with the final concentrations shown in the figure to make the total volume of each well 0.2ml. 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an Aapplication of a benzamide compound in preparation of a medicine for activating latent human immunodeficiency viruses, and an application of a composition of the benzamide compound and one or more anti-human immunodeficiency virus medicines in preparation of a medicine for inhibiting and / or eliminating latent human immunodeficiency viruses. Due to adoption of the medicine, the latent human immunodeficiency viruses can be efficiently and continuously activating latent human immunodeficiency viruses for a long time, and thus acquired immune deficiency syndrome treatment is possible.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of benzamide compounds in the preparation of drugs for activating latent HIV. Background technique [0002] Acquired Immunodeficiency Syndrome (AIDS) is an infectious disease caused by HIV infection that seriously endangers human health. It is one of the most serious public diseases facing mankind at present. Its effective prevention and complete cure are still It's a worldwide problem. At the 19th World AIDS Conference (http: / / aids2012.org) held on July 22, 2012, international AIDS experts agreed that "humanity has ushered in a major turning point in the prevention and treatment of AIDS". It has gradually transformed from a 'terminal disease of the century' to a chronic disease". This is because there are about 30 kinds of antiretroviral drugs in the world that can form an effective treatment method. If combined drugs, that is, "Highly Active Antiretroviral Therapy (HAA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4406A61K31/551A61K31/496A61P31/18A61P43/00
Inventor 潘彦斌冒彬康加深姜世勃陆路孙志武
Owner ARIS NANTONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com